Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Dainippon offers $200mm up front and over $2bn in earn-outs to buy Boston Biomedical

Executive Summary

Less than a year after striking up their first collaboration together, Japanese drug company Dainippon Sumitomo Pharma Co. Ltd. (DSP) has decided to acquire private partner Boston Biomedical Inc. (developing oncology therapies that target cancer stem cells). DSP will pay $200mm up front and up to $2.43bn in earn-outs ($540mm based on development of Boston Biomedical’s candidates and up to $1.89bn in various sales milestones, with the maximum paid when $4bn in net sales are achieved in any fiscal year.)
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register